Immune Repertoire Sequencing Market to Reach US$ 186.9 Million by 2030: Research by Reports and Insights…

A recently published report titled, “Immune Repertoire Sequencing Market: Opportunity Analysis and Future Assessment 2022-2030” offers a thorough and profound assessment on the market stature along with the top leading facts and figures, definition, overview, expert opinions, SWOT analysis, as well as the recent developments of the market all around the world. The market report also computes the market size, market sales, revenue, price, market share and gross margin and market forecast, growth rate and cost structure. The report estimates the revenue created from the sales and technologies by various application segments.

The immune repertoire sequencing market is estimated to reach at a value of US$ 111.0 Mn by the end of 2022 and expected to reach at a value of US$ 186.9 Mn by 2030 with a significant CAGR of 6.7%

Request To Download Sample of Immune Repertoire Sequencing Market Report:

Immune repertoire can be perceived as the aggregate of T cell receptors and B cell receptors (also named immunoglobulin) that makes up the organism’s adaptive immune system. The rapid progress and advances in next generation sequencing (NGS) have allowed the establishment of a new and robust technology named as immune repertoire sequencing. The immune repertoire sequencing helps for inquiring the complementary determining region of these receptors.

Immune repertoire sequencing has assisted in profiling the antigen-specific information within lymphocytes and has turned out to be essentially crucial to understand the body’s auto-defense mechanism opposed to foreign agents. It is important to note that the Immune repertoire sequencing has turned out to be an extremely helpful instrument to quantify the configuration of B or T cell antigen receptor repertoires in basic research, such as immune repertoire development, vaccination, and lymphocyte lineage tracking, as well as in several different clinical settings, such as hematopoietic stem cell transplant recovery monitoring, minimal residual disease (MRD) monitoring, and cancer patient prognosis.

Having said that, the early IR-seq experiments have observed high PCR and sequencing errors that restricted their capability to perform unerring repertoire diversity and abundance quantification. Nevertheless, the continuous research activities for the same has resulted in several successful advances and progress in the present times. In present, the immune repertoire sequencing is employed in the comprehensive range of applications such as cancer immunotherapy, biomarkers discovery, asthma and allergies, infectious diseases, research and much more. Attributing to which, the global immune repertoire sequencing market is projected to rise significantly over the coming years.

Key Takeaways from the Market Study

  •         The immune repertoire sequencing market is estimated to reach at a value of US$ 111.0 Mn by the end of 2022 and expected to reach at a value of US$ 186.9 Mn by 2030 with a significant CAGR of 6.7%
  •         The assay kits product segment in immune repertoire sequencing market is expected to create an incremental opportunity of US$ 25.6 Mn during the forecast period
  •         In 2022, cancer immunotherapy application segment accounted for the largest market share and expected to grow at 7.9% CAGR during the forecast period.
  •         In 2022, the diagnostics labs end user segment accounted for the largest market share
  •         Asia Pacific region is expected to remain the prominent region in the global market and is estimated to remain the fastest growing region
  •         The U.S. immune repertoire sequencing market is expected to increase 1.8X during the forecast period


Increasing usage of IR-seq in biomarker discovery

  • The immune repertoire sequencing majorly serves its utility in outlining T- and B-cell receptor repertoires in an individual, which has paved the way to a comprehensive reservoir of information on procured immunity opposed to several pathogens. It is believed that the next-generation immune repertoire sequencing has enabled several researchers across the world to make refined and advanced immuno-bioinformatics probes. It has stimulated fascination and interest amongst the research community and biopharmaceutical industries in the field of clinical development of vaccine design, antibody engineering, and cellular immunotherapy. It is important to have a better understanding of the immune repertoire with the emergence of immunotherapy and precision medicine, where treatments are being formulated that are custom-made to an individual for higher efficacy. There are several treatments in development and put to use that impact the immune system.
  • Assessing the immune repertoire is likely to help to anticipate therapeutic results and be employed to monitor the effects of treatment. Notably, the immune repertoire sequencing is majorly employed in biomarker discovery in order to improve the hit ratio and cost-efficiency of rational drug development. For example, in November 2017, the Center for Commercialization of Cancer Immunotherapy (C3i) began providing T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit in Canada. In addition to that, there are several organizations seeking to look for outcomes with regard to biomarkers in the immune system, thereby projected to drive the market growth over the years.


Reports and Insights Study identifies some of the key participating players in Illumina, Inc., Pacific Biosciences of California, Inc, Agilent Technologies, Inc, Oxford Nanopore Technologies, Ltd, Qiagen N.V., ThermoFisher Scientific, F. Hoffmann-La Roche Ltd, Takara Bio, Inc, Bristol-Myers Squibb, Adaptive Biotechnologies, Archerdx, INC., Irepertoire, INC., CD Genomics, and BGI.

Immune Repertoire Sequencing Market Segmentation

The global Immune Repertoire Sequencing market is segmented on the basis of type, configuration, operation, application, end use, and region.

By Product

           Assay Kits

               TCR Kits

               BCR Kits


                TCR Analysis Solutions

               BCR Analysis Solutions

               TCR & BCR Analysis Solutions





               Sequencing Services

               Data Analysis Services

               Pre-Sequencing Services

By Subject Type



By Application

          Pharmagenomics Based Drug Recovery

                Next Generation Sequencing

                Polymerase Chain Reaction


         Biomarker Discovery

         Autoimmune Diseases

         Cancer Immunotherapy

         Infectious Disease Research

         Asthma and Allergy Research

         Vaccine Development

         Immunodeficiency Identification


By End User

        Diagnostic Labs

        Pharmaceutical and Biotech Companies

        Research Institutes


By Region

        North America

        Latin America


        Asia Pacific

        Middle East


Contact Us

Reports and Insights

Tel: +1-(718)-312-8686

For Sales Query:

For New Topics & Other Info: